Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 490 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Shock Lung Clear all
Completed Phase 3 Interventional Results available

Reevaluation Of Systemic Early Neuromuscular Blockade

NCT02509078
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Cisatracurium Besylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 24, 2026, 5:10 PM EDT
Enrolling by invitation Not applicable Interventional

Safety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure

NCT06938217
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Mechanical Ventilation, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Low-flow ECMO
Device
Lead sponsor
Institute for Extracorporeal Life Support
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Carbon Monoxide to Prevent Lung Inflammation

NCT00094406
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Bronchoscopy, Bronchoalveolar lavage, Endotoxin, Carbon Monoxide
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 40 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional

Work of Breathing During Non-invasive Ventilation in Premature Neonates

NCT02788110
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Bronchopulmonary Dysplasia
Interventions
Noninvasive neurally adjusted ventilatory assist (NIV NAVA), Nasal intermittent positive pressure ventilation (NIPPV)
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 24, 2026, 5:10 PM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 5:10 PM EDT
Suspended Phase 2 Interventional

Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

NCT07123961
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS)
Interventions
High Driving Pressure Mechanical Ventilation, Low Driving Pressure Mechanical Ventilation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Weeks to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supine or Prone Position After Caesarean Birth

NCT01310153
View directory record Official record
Conditions
Respiratory Distress, Transient Tachypnea of the Newborn, Delayed Transition of the Newborn, Persistent Pulmonary Hypertension
Interventions
prone positioning, Supine
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 24, 2026, 5:10 PM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 24, 2026, 5:10 PM EDT
Recruiting No phase listed Observational

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077
View directory record Official record
Conditions
Lung Cancer Diagnosis
Interventions
blood draw
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
50 Years and older
Enrollment
20,000 participants
Timeline
2023 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Stamford, Connecticut • DeLand, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 24, 2026, 5:10 PM EDT
Withdrawn Not applicable Interventional

Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide

NCT01927237
View directory record Official record
Conditions
Low Tidal Volume Ventilation, Acute Respiratory Distress Syndrome
Interventions
HLR, EHR
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 24, 2026, 5:10 PM EDT
Recruiting Phase 2 Interventional

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

NCT06476132
View directory record Official record
Conditions
Lung Transplant
Interventions
Belumosudil, Placebo for Belumosudil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

NCT05387278
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Interventions
EV-Pure™ and WJ-Pure™, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 5:10 PM EDT
Not listed Not applicable Interventional

Efficacy of Oxepa Enteral Feeding in LTAC (Long Term Acute Care Hospital) Patients on Chronic Ventilation- a Pilot Study

NCT02208700
View directory record Official record
Conditions
Acute Lung Injury, Mechanical Ventilation Complication, Dietary Modification
Interventions
Oxepa, Jevity 1.5
Other
Lead sponsor
Grace Hospital, Cleveland, Ohio
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 24, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional

Early Inhaled Nitric Oxide for Respiratory Failure in Newborns

NCT00005773
View directory record Official record
Conditions
Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
Interventions
Inhaled Nitric Oxide, Standard iNO therapy
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 14 Days
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 24, 2026, 5:10 PM EDT
Completed No phase listed Observational

The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol

NCT01714583
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional

Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants

NCT01203488
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Respiration, Artificial, Respiratory Distress Syndrome, Newborn, Sepsis
Interventions
Vitamin A, Sham Procedure
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Hours
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 24, 2026, 5:10 PM EDT
Terminated No phase listed Observational

Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care

NCT00887731
View directory record Official record
Conditions
Respiratory Distress Syndrome, Hyperoxia, Prematurity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 3 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 24, 2026, 5:10 PM EDT
Not yet recruiting Phase 2 Interventional

Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?

NCT07447739
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD)
Interventions
Betamethasone
Drug
Lead sponsor
Khang Nguyen
Other
Eligibility
Up to 28 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 24, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 24, 2026, 5:10 PM EDT
Recruiting Phase 3 Interventional

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

NCT05960929
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Interventions
Infasurf Aero™
Combination Product
Lead sponsor
ONY
Industry
Eligibility
29 Weeks to 36 Weeks
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 24, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 24, 2026, 5:10 PM EDT